New biologic mirikizumab put to the test against standard therapies for IBD
NCT ID NCT07686757
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study compares the real-world effectiveness of mirikizumab against standard biologic therapies for adults with ulcerative colitis or Crohn's disease. Researchers will track whether mirikizumab reduces the need for extra medical care, like emergency visits or treatment changes, over 18 months. Participants receive either mirikizumab or another biologic as part of their routine care, and their health data and symptom reports are collected to see which approach leads to better disease control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mirikizumab
- What this could lead to
- If mirikizumab works better than current biologics, it could offer a new, more effective option for controlling inflammatory bowel disease and reducing hospital visits.
- What could go wrong
- This is a real-world study, not a tightly controlled trial, so results may be less clear. Mirikizumab may not prove superior to existing treatments, and individual responses vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stool test may predict gut healing in ulcerative colitis
- Can better detection of precancerous lesions in IBD prevent colorectal cancer?
- New staining technique could sharpen healing assessment in IBD
- Real-World study tests Once-Daily pill for ulcerative colitis in chinese adults
- Can a higher dose of upadacitinib rescue ulcerative colitis patients when standard treatment fails?
- Study aims to keep workers with chronic illnesses on the job